

Michael R Zile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993633/publications.pdf>

Version: 2024-02-01

358
papers

41,823
citations

2671

95
h-index

2680

193
g-index

364
all docs

364
docs citations

364
times ranked

24276
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiotensinâ€“Nepriylsin Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	13.9	5,052
2	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	13.9	1,663
3	Angiotensinâ€“Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
4	Diastolic Heart Failure â€” Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle. <i>New England Journal of Medicine</i> , 2004, 350, 1953-1959.	13.9	1,319
5	New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I. <i>Circulation</i> , 2002, 105, 1387-1393.	1.6	1,078
6	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet</i> , 2012, 380, 1387-1395.	6.3	990
7	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2016, 134, 73-90.	1.6	747
8	New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II. <i>Circulation</i> , 2002, 105, 1503-1508.	1.6	696
9	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.	1.2	591
10	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
11	Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure. <i>Circulation</i> , 2006, 114, 397-403.	1.6	539
12	Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2015, 131, 1247-1259.	1.6	509
13	Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1073-1079.	1.2	483
14	Transition From Chronic Compensated to Acute Decompensated Heart Failure. <i>Circulation</i> , 2008, 118, 1433-1441.	1.6	475
15	Heart Failure With a Normal Ejection Fraction. <i>Circulation</i> , 2001, 104, 779-782.	1.6	437
16	Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, 2491-2501.	1.6	418
17	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
18	Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases. <i>Circulation</i> , 2006, 113, 2089-2096.	1.6	363

#	ARTICLE	IF	CITATIONS
19	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 1062-1073.	2.9	358
20	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017, 377, 41-51.	13.9	355
21	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015, 36, 1990-1997.	1.0	335
22	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
23	Left Ventricular Structural Remodeling in Health and Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1733-1740.	1.2	331
24	Matrix Metalloproteinase Inhibition During the Development of Congestive Heart Failure. <i>Circulation Research</i> , 1999, 85, 364-376.	2.0	319
25	Cardiac macrophages promote diastolic dysfunction. <i>Journal of Experimental Medicine</i> , 2018, 215, 423-440.	4.2	314
26	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <i>Lancet</i> , The, 2007, 369, 2079-2087.	6.3	308
27	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2010, 121, 1393-1405.	1.6	290
28	The Effect of Alagebrium Chloride (ALT-711), a Novel Glucose Cross-Link Breaker, in the Treatment of Elderly Patients With Diastolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2005, 11, 191-195.	0.7	278
29	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.	1.9	272
30	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2425-2436.	1.2	271
31	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
32	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	260
33	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 333-340.	5.5	258
34	Left Ventricular Diastolic Dysfunction and Diastolic Heart Failure. <i>Annual Review of Medicine</i> , 2004, 55, 373-394.	5.0	256
35	Left Ventricular Systolic Performance, Function, and Contractility in Patients With Diastolic Heart Failure. <i>Circulation</i> , 2005, 111, 2306-2312.	1.6	255
36	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244

#	ARTICLE	IF	CITATIONS
37	Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 324-331.	1.6	238
38	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	1.9	238
39	Contractile Behavior of the Left Ventricle in Diastolic Heart Failure. <i>Circulation</i> , 2006, 113, 296-304.	1.6	232
40	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	1.6	224
41	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.	1.6	219
42	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	1.6	218
43	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. <i>Lancet</i> , The, 2021, 398, 991-1001.	6.3	218
44	Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study – The Digitalis Investigation Group study was conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the Digitalis Investigation Group Investigators. This manuscript was prepared using a limited access data set obtained by the National Heart, Lung, and Blood Institute and does not necessarily reflect the opinions or views of the Digitalis Investigation Gro. <i>American Journal of Cardiology</i> , 2007, 99, 393-398.	0.7	217
45	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 27-35.	1.6	216
46	Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition. <i>Circulation</i> , 2003, 107, 618-625.	1.6	212
47	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 487-496.	1.9	204
48	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.	2.9	203
49	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1096-1103.	2.9	194
50	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015, 36, 2576-2584.	1.0	187
51	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.	2.9	184
52	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	2.9	183
53	Plasma Biomarkers That Reflect Determinants of Matrix Composition Identify the Presence of Left Ventricular Hypertrophy and Diastolic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 246-256.	1.6	183
54	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.	1.6	177

#	ARTICLE	IF	CITATIONS
55	Specific Temporal Profile of Matrix Metalloproteinase Release Occurs in Patients After Myocardial Infarction. <i>Circulation</i> , 2006, 114, 1020-1027.	1.6	176
56	Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. <i>Journal of Clinical Investigation</i> , 2012, 122, 3919-3930.	3.9	175
57	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.	2.9	173
58	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 795-806.	1.2	173
59	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019, 73, 29-40.	1.2	168
60	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017, 38, 1132-1143.	1.0	160
61	Renal effects of the angiotensin receptor neprilysin inhibitor <sc>LCZ696</sc> in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
62	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153
63	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	150
64	Baseline characteristics and treatment of patients in Prospective comparison of <sc>ARNI</sc> with <sc>ACEI</sc> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<sc>PARADIGM-HF</sc>). <i>European Journal of Heart Failure</i> , 2014, 16, 817-825.	2.9	148
65	Cytoskeletal Mechanics in Pressure-Overload Cardiac Hypertrophy. <i>Circulation Research</i> , 1997, 80, 281-289.	2.0	147
66	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. <i>JAMA Cardiology</i> , 2017, 2, 79.	3.0	143
67	Effects of Age on Plasma Matrix Metalloproteinases (MMPs) and Tissue Inhibitor of Metalloproteinases (TIMPs). <i>Journal of Cardiac Failure</i> , 2007, 13, 530-540.	0.7	142
68	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
69	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 753-760.	0.7	141
70	Membrane-Associated Matrix Proteolysis and Heart Failure. <i>Circulation Research</i> , 2013, 112, 195-208.	2.0	140
71	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	1.2	139
72	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.	1.2	138

#	ARTICLE	IF	CITATIONS
73	The Natural History of Left Ventricular Geometry in the Community. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 870-878.	2.3	134
74	From Systemic Inflammation to Myocardial Fibrosis. <i>Circulation Research</i> , 2021, 128, 1451-1467.	2.0	132
75	Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 614-619.	5.1	131
76	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 666.	3.0	130
77	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.	1.6	130
78	The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2005, 11, 576-585.	0.7	129
79	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	2.9	129
80	Pressure Overload-Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic Function. <i>Circulation</i> , 2009, 119, 269-280.	1.6	127
81	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 547-554.	5.5	124
82	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1-13.	1.2	121
83	Chronic Ambulatory Intracardiac Pressures and Future Heart Failure Events. <i>Circulation: Heart Failure</i> , 2010, 3, 580-587.	1.6	120
84	Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H149-H158.	1.5	119
85	Integrin Activation and Focal Complex Formation in Cardiac Hypertrophy. <i>Journal of Biological Chemistry</i> , 2000, 275, 35624-35630.	1.6	118
86	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	1.2	118
87	Cytoskeletal Role in the Transition From Compensated to Decompensated Hypertrophy During Adult Canine Left Ventricular Pressure Overloading. <i>Circulation Research</i> , 1998, 82, 751-761.	2.0	117
88	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
89	Effects of Gene Deletion of the Tissue Inhibitor of the Matrix Metalloproteinase-type 1 (TIMP-1) on Left Ventricular Geometry and Function in Mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 109-120.	0.9	115
90	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	1.0	114

#	ARTICLE	IF	CITATIONS
91	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	1.2	114
92	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112
93	Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H614-H622.	1.5	110
94	Changes in extracellular collagen matrix alter myocardial systolic performance. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 284, H122-H132.	1.5	109
95	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019, 21, 23-36.	2.9	102
96	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016, 68, 241-248.	1.2	101
97	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	1.2	97
98	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018, 15, e1002541.	3.9	97
99	Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure. <i>Circulation Research</i> , 2003, 92, 177-185.	2.0	96
100	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006541.	1.6	96
101	Cardiosphere-Derived Cells Reverse Heart Failure With Preserved Ejection Fraction in Rats by Decreasing Fibrosis and Inflammation. <i>JACC Basic To Translational Science</i> , 2016, 1, 14-28.	1.9	95
102	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 129-137.	2.9	95
103	Outcomes and Effect of Treatment According to Etiology in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 457-465.	1.9	94
104	Systolic and Diastolic Mechanics in Stress Cardiomyopathy. <i>Circulation</i> , 2014, 129, 1659-1667.	1.6	93
105	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	93
106	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015, 373, 2289-2290.	13.9	92
107	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 561-568.	1.6	91
108	Myocardial remodeling with aortic stenosis and after aortic valve replacement: Mechanisms and future prognostic implications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 656-664.	0.4	88

#	ARTICLE	IF	CITATIONS
109	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015, 17, 1066-1074.	2.9	85
110	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of <sc>PARADIGM-HF</sc> and <sc>ATMOSPHERE</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2123-2133.	2.9	85
111	Efficacy of Sacubitril/Valsartan Relative to A Prior Decompensation. <i>JACC: Heart Failure</i> , 2016, 4, 816-822.	1.9	84
112	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 498.	3.0	84
113	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018, 205, 1-11.	1.2	84
114	Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2690-2707.	1.2	83
115	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQq1 1 0.784314 rgBT /Over Therapy. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	83
116	New Molecular Mechanism in Diastolic Heart Failure. <i>Circulation</i> , 2006, 113, 1922-1925.	1.6	82
117	Chronic Baroreflex Activation: A Potential Therapeutic Approach to Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2011, 17, 167-178.	0.7	81
118	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	1.6	80
119	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (Iá Preserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	2.9	80
120	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	1.0	80
121	Continuous Hemodynamic Monitoring in Patients With Mild to Moderate Heart Failure: Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) Trial. <i>Congestive Heart Failure</i> , 2011, 17, 248-254.	2.0	79
122	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	79
123	Effect of Praliguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1522.	3.8	79
124	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
125	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	1.6	78
126	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77

#	ARTICLE	IF	CITATIONS
127	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020, 76, 503-514.	1.2	77
128	Myocardial fibroblast-matrix interactions and potential therapeutic targets. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 70, 92-99.	0.9	76
129	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
130	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
131	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
132	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	1.9	72
133	Microtubule Depolymerization Normalizes In Vivo Myocardial Contractile Function in Dogs With Pressure-Overload Left Ventricular Hypertrophy. <i>Circulation</i> , 2000, 102, 1045-1052.	1.6	71
134	Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. <i>Nature Communications</i> , 2022, 13, 203.	5.8	71
135	Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 123-130.	1.9	70
136	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2018, 24, 682-694.	0.7	70
137	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013114.	1.6	69
138	Integrating the Myocardial Matrix Into Heart Failure Recognition and Management. <i>Circulation Research</i> , 2013, 113, 725-738.	2.0	67
139	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
140	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	1.2	67
141	Adverse Left Ventricular Remodeling in Community-Dwelling Older Adults Predicts Incident Heart Failure and Mortality. <i>JACC: Heart Failure</i> , 2014, 2, 512-522.	1.9	67
142	Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1080-1084.	1.2	66
143	Premorbid Determinants of Left Ventricular Dysfunction in a Novel Model of Gradually Induced Pressure Overload in the Adult Canine. <i>Circulation</i> , 1997, 95, 1601-1610.	1.6	65
144	Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 501-515.	1.1	64

#	ARTICLE	IF	CITATIONS
145	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.	2.9	64
146	Diastolic Heart Failure: Definitions and Terminology. <i>Progress in Cardiovascular Diseases</i> , 2005, 47, 307-313.	1.6	63
147	Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 217-225.	1.6	63
148	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	1.9	63
149	Role of microtubules in the contractile dysfunction of hypertrophied myocardium. <i>Journal of the American College of Cardiology</i> , 1999, 33, 250-260.	1.2	62
150	Dual-Source CT Imaging to Plan Transcatheter Aortic Valve Replacement: Accuracy for Diagnosis of Obstructive Coronary Artery Disease. <i>Radiology</i> , 2015, 275, 80-88.	3.6	62
151	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 760-768.	2.9	62
152	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
153	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013, 34, 676-683.	1.0	59
154	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	3.0	59
155	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to) <i>Tj ETQq1 1 0,784314 rgBT /Over</i> 11, e004446.	1.6	58
156	Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H2324-H2335.	1.5	57
157	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709.	2.9	56
158	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	1.9	56
159	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	1.6	55
160	Patterns of Structural and Functional Remodeling of the Left Ventricle in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 459-462.	0.7	54
161	Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 215-223.	0.4	54
162	The prognostic value of troponin T and N-terminal pro-B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019, 21, 40-49.	2.9	54

#	ARTICLE	IF	CITATIONS
163	β_3 Integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. <i>FASEB Journal</i> , 2009, 23, 2759-2771.	0.2	53
164	Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, 128-134.	0.7	53
165	HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. <i>Circulation: Heart Failure</i> , 2015, 8, 1094-1104.	1.6	53
166	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
167	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
168	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	1.9	53
169	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	1.9	53
170	Constitutive Properties of Adult Mammalian Cardiac Muscle Cells. <i>Circulation</i> , 1998, 98, 567-579.	1.6	52
171	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the PResERVE study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	2.9	52
172	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	52
173	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018, 138, 2763-2773.	1.6	52
174	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	2.9	52
175	Application of Implantable Hemodynamic Monitoring in the Management of Patients With Diastolic Heart Failure: A Subgroup Analysis of the COMPASS-HF Trial. <i>Journal of Cardiac Failure</i> , 2008, 14, 816-823.	0.7	51
176	β_3 Integrin in Cardiac Fibroblast Is Critical for Extracellular Matrix Accumulation during Pressure Overload Hypertrophy in Mouse. <i>PLoS ONE</i> , 2012, 7, e45076.	1.1	50
177	Effects of Exercise on Left Ventricular Systolic and Diastolic Properties in Patients With Heart Failure and a Preserved Ejection Fraction Versus Heart Failure and a Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 508-516.	1.6	50
178	In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H314-H326.	1.5	48
179	Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 1—Insights into Pathophysiology. <i>Journal of Cardiac Failure</i> , 2011, 17, 282-291.	0.7	48
180	Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H234-H240.	1.5	46

#	ARTICLE	IF	CITATIONS
181	Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C972-C982.	2.1	46
182	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	46
183	Mitochondrial biogenesis induced by the β_2 -adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. <i>Kidney International</i> , 2019, 96, 656-673.	2.6	44
184	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
185	Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H92-H100.	1.5	43
186	Cardiopulmonary Exercise Variables in Diastolic Versus Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 203-206.	0.7	42
187	Lactosylceramide contributes to mitochondrial dysfunction in diabetes. <i>Journal of Lipid Research</i> , 2016, 57, 546-562.	2.0	41
188	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019, 214, 18-27.	1.2	41
189	Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 669-679.	1.2	41
190	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	1.4	40
191	Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E1027-E1035.	1.8	40
192	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Nephilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
193	Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1429-H1437.	1.5	39
194	Age and SPARC Change the Extracellular Matrix Composition of the Left Ventricle. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	39
195	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nephilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1226.	3.0	38
196	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.	2.9	38
197	Heart Failure in Aortic Stenosis - Improving Diagnosis and Treatment. <i>New England Journal of Medicine</i> , 2003, 348, 1735-1736.	13.9	37
198	Lack of relationship between doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. <i>American Heart Journal</i> , 2004, 148, 530.	1.2	37

#	ARTICLE	IF	CITATIONS
199	Myosin Cross-Bridge Dynamics in Patients With Hypertension and Concentric Left Ventricular Remodeling. <i>Circulation: Heart Failure</i> , 2012, 5, 803-811.	1.6	36
200	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 169-176.	2.9	36
201	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	1.0	36
202	Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H1128-H1134.	1.5	35
203	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.	1.6	35
204	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2016, 134, 1785-1787.	1.6	35
205	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	0.7	35
206	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	1.2	35
207	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1861-1871.	1.2	34
208	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2056-2064.	2.9	34
209	Continuous Aortic Flow Augmentation. <i>Circulation</i> , 2005, 112, 3107-3114.	1.6	33
210	Natural History of Concentric Left Ventricular Geometry in Community-Dwelling Older Adults Without Heart Failure During Seven Years of Follow-Up. <i>American Journal of Cardiology</i> , 2011, 107, 321-324.	0.7	33
211	Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1696-H1706.	1.5	33
212	Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 2093-2101.	2.9	33
213	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1662-1671.	2.9	33
214	Cardiac-Specific Expression and Hypertrophic Upregulation of the Feline Na ⁺ -Ca ²⁺ Exchanger Gene H1-Promoter in a Transgenic Mouse Model. <i>Circulation Research</i> , 2002, 90, 158-164.	2.0	32
215	Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy. <i>Circulation</i> , 2008, 118, 1241-1249.	1.6	32
216	HFpEF: Cardiovascular Abnormalities Not Just Comorbidities. <i>Circulation: Heart Failure</i> , 2012, 5, 669-671.	1.6	32

#	ARTICLE	IF	CITATIONS
217	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	1.2	32
218	Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H958-H967.	1.5	32
219	Effect of catheter positioning on the variability of measured gradient in aortic stenosis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993, 30, 287-292.	0.7	31
220	STAT3 Activation in Pressure-Overloaded Feline Myocardium: Role for Integrins and the Tyrosine Kinase BMX. <i>International Journal of Biological Sciences</i> , 2008, 4, 184-199.	2.6	30
221	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 733-740.	1.6	30
222	Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 291-298.	1.3	30
223	Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.	2.9	30
224	Renin-Angiotensin Inhibition in Diastolic Heart Failure and Chronic Kidney Disease. <i>American Journal of Medicine</i> , 2013, 126, 150-161.	0.6	29
225	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019545.	1.6	29
226	Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H2173-H2182.	1.5	28
227	In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	28
228	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	2.9	28
229	A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H2231-H2241.	1.5	27
230	Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. <i>Histochemistry and Cell Biology</i> , 2010, 134, 23-30.	0.8	27
231	Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a <i>Pkd1</i> mouse model. <i>FASEB Journal</i> , 2016, 30, 370-379.	0.2	27
232	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 266, 187-192.	0.8	27
233	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018, 204, 139-150.	1.2	27
234	The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. <i>European Heart Journal</i> , 2022, 43, 2603-2618.	1.0	27

#	ARTICLE	IF	CITATIONS
235	Hospitalizations Due to Unstable Angina Pectoris in Diastolic and Systolic Heart Failure. American Journal of Cardiology, 2007, 99, 460-464.	0.7	26
236	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 320-328.	0.4	26
237	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. American Journal of Medicine, 2018, 131, 1473-1481.	0.6	26
238	Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1270-H1285.	1.5	25
239	A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1) Tj ETQq1d.0.784324 rgBT /O	0.7	25
240	Distribution of Left Ventricular Ejection Fraction in Patients With Ischemic and Hypertensive Heart Disease and Chronic Heart Failure. American Journal of Cardiology, 2009, 104, 1413-1415.	0.7	25
241	Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 2â€”Use in Automated Detection. Journal of Cardiac Failure, 2011, 17, 366-373.	0.7	25
242	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	1.6	25
243	Mechanisms of cardiac hypertrophy in canine volume overload. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H65-H74.	1.5	24
244	Treating Diastolic Heart Failure With Statins. Circulation, 2005, 112, 300-303.	1.6	24
245	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2019, 4, 924-937.	1.9	24
246	The relationship between renal impairment and left ventricular structure, function, and ventricularâ€”arterial interaction in hypertension. Journal of Hypertension, 2011, 29, 1829-1836.	0.3	23
247	Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Failure, 2021, 8, 1706-1710.	1.4	23
248	Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. American Heart Journal, 2006, 152, 246-252.	1.2	22
249	Changes in Plasma Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of MMPs in Stress-Induced Cardiomyopathy. Journal of Cardiac Failure, 2012, 18, 487-492.	0.7	22
250	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. Circulation: Heart Failure, 2015, 8, 717-724.	1.6	22
251	Angiotensin Receptor-Nepriylsin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. Circulation: Heart Failure, 2020, 13, e006696.	1.6	22
252	Chronic Heart Failure: A Report From the Dartmouth Diastole Discourses. Congestive Heart Failure, 2006, 12, 162-165.	2.0	21

#	ARTICLE	IF	CITATIONS
253	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2015, 3, 478-486.	1.9	21
254	How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1010-1017.	1.7	10
255	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019, 12, e005766.	1.6	21
256	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>ESC Heart Failure</i> , 2021, 8, 1130-1138.	1.4	21
257	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2021, 9, 627-635.	1.9	21
258	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 418-427.	1.9	20
259	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e019238.	1.6	20
260	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1518-1524.	2.9	20
261	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 551-561.	2.9	20
262	Mechanistic Relationship Between Membrane Type-1 Matrix Metalloproteinase and the Myocardial Response to Pressure Overload. <i>Circulation: Heart Failure</i> , 2014, 7, 340-350.	1.6	19
263	Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 132-139.	0.6	19
264	Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. <i>Hypertension Research</i> , 2015, 38, 551-559.	1.5	18
265	Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. <i>Circulation: Heart Failure</i> , 2016, 9, e002543.	1.6	18
266	Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 49.	1.1	18
267	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346.	1.9	18
268	Effects of Autonomic Modulation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 910-912.	1.2	17
269	Relation of N-Terminal Pro-B-Type Natriuretic Peptide With Diastolic Function in Hypertensive Heart Disease. <i>American Journal of Hypertension</i> , 2013, 26, 1234-1241.	1.0	17
270	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	2.9	17

#	ARTICLE	IF	CITATIONS
271	The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. <i>International Journal of Cardiology</i> , 2016, 215, 521-526.	0.8	17
272	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
273	Plasma Monitoring of the Myocardial Specific Tissue Inhibitor of Metalloproteinase-4 After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2005, 11, 124-130.	0.7	16
274	A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. <i>Journal of Cardiology</i> , 2015, 66, 253-262.	0.8	16
275	Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F79-F87.	1.3	16
276	Attenuation of accelerated renal cystogenesis in <i>Pkd1</i> mice by renin-angiotensin system blockade. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F210-F218.	1.3	16
277	Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. <i>American Journal of Cardiology</i> , 2019, 124, 756-762.	0.7	16
278	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy <i>Comment on:</i> "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi <i>et al.</i>. <i>ESC Heart Failure</i> , 2018, 5, 1069-1071.	1.4	15
279	Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release. <i>Journal of the American Heart Association</i> , 2019, 8, e010332.	1.6	15
280	SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H604-H612.	1.5	15
281	Diastolic heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000, 2, 439-450.	0.4	14
282	Prediction of worsening heart failure events and all-cause mortality using an individualized risk stratification strategy. <i>ESC Heart Failure</i> , 2020, 7, 4277-4289.	1.4	14
283	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2370-2379.	2.9	14
284	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). <i>American Heart Journal</i> , 2020, 222, 183-190.	1.2	14
285	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. <i>American Journal of Medicine</i> , 2021, 134, e252-e263.	0.6	14
286	Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
287	Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	14
288	Left ventricular hypertrophy in a canine model of reversible pressure overload. <i>Cardiovascular Research</i> , 1992, 26, 580-585.	1.8	13

#	ARTICLE	IF	CITATIONS
289	Hemodynamic Determinants of Echocardiographicallyâ€Derived Indices of Left Ventricular Filling. <i>Echocardiography</i> , 1992, 9, 289-300.	0.3	13
290	Pressure overload generates a cardiac-specific profile of inflammatory mediators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H331-H340.	1.5	13
291	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
292	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGONâ€HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
293	Left Ventricular Diastolic Function and Exercise Capacity in Community-Dwelling Adults â‰¥65 Years of Age Without Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 735-740.	0.7	12
294	Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H752-H761.	1.5	12
295	Estrogen-Related Receptor $\hat{\pm}$ (ERR $\hat{\pm}$) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions. <i>International Journal of Cardiology</i> , 2015, 187, 393-400.	0.8	12
296	Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 1232.	3.0	12
297	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <sc>PARAGONâ€HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 776-784.	2.9	12
298	Diastolic heart failure: Diagnosis and treatment. <i>Clinical Cornerstone</i> , 2000, 3, 13-24.	1.0	11
299	Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals. <i>Circulation: Heart Failure</i> , 2015, 8, 17-24.	1.6	11
300	Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. <i>Heart and Vessels</i> , 2017, 32, 1202-1213.	0.5	11
301	Should We Test for Diastolic Dysfunction? How and How Often?. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 297-309.	2.3	11
302	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1358-1365.	1.5	11
303	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <sc>PARADIGMâ€HF</sc> analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1346-1356.	2.9	11
304	Is Biventricular Fibrosis the Mediator of Late Complications in Tetralogy of Fallot?. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 11-13.	2.3	10
305	Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e022930.	1.6	10
306	Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure. <i>Journal of the American Heart Association</i> , 2022, 11, e024095.	1.6	10

#	ARTICLE	IF	CITATIONS
307	Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. <i>Journal of Palliative Medicine</i> , 2017, 20, 1068-1073.	0.6	9
308	Safety and Feasibility of a Nocturnal Heart Rate Elevation—Exploration of a Novel Treatment Concept. <i>Journal of Cardiac Failure</i> , 2019, 25, 67-71.	0.7	9
309	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020, 7, 3355-3364.	1.4	9
310	Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload. <i>JACC Basic To Translational Science</i> , 2020, 5, 463-480.	1.9	9
311	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Medicine</i> , 2020, 133, 1187-1194.	0.6	9
312	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. <i>Human Molecular Genetics</i> , 2021, 29, 3504-3515.	1.4	9
313	Could Modification of Titin Contribute to an Answer for Heart Failure With Preserved Ejection Fraction?. <i>Circulation</i> , 2016, 134, 1100-1104.	1.6	8
314	Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. <i>Physiological Reports</i> , 2017, 5, e13462.	0.7	8
315	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1234-1248.	1.5	8
316	Changes in the crystallographic structures of cardiac myosin filaments detected by polarization-dependent second harmonic generation microscopy. <i>Biomedical Optics Express</i> , 2019, 10, 3183.	1.5	8
317	A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone. <i>Circulation</i> , 2021, 144, 1269-1271.	1.6	8
318	Renal Sympathetic Denervation for Blood Pressure Control: A Review of the Current Evidence and Ongoing Studies. <i>Journal of Clinical Hypertension</i> , 2014, 16, 331-341.	1.0	7
319	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2021, 10, e018127.	1.6	7
320	Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 155.	0.7	7
321	In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse. <i>Molecular and Cellular Biochemistry</i> , 2012, 367, 205-213.	1.4	6
322	Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. <i>American Journal of Medicine</i> , 2021, 134, 797-804.	0.6	6
323	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 672-677.	2.9	6
324	Neuromodulation Device Therapy for Treatment of Hypertensive Heart Disease. <i>Circulation Journal</i> , 2013, 77, 1351-1363.	0.7	5

#	ARTICLE	IF	CITATIONS
325	Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. <i>Clinical Cardiology</i> , 2020, 43, 1501-1510.	0.7	5
326	Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?. <i>Heart Rhythm</i> 02, 2021, 2, 37-45.	0.6	5
327	Influence of Study Discontinuation during the Run-in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGON-HF Trial. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5
328	Mechanisms that limit regression of myocardial fibrosis following removal of left ventricular pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H165-H175.	1.5	5
329	Pathophysiology of Diastolic Heart Failure: Relaxation and Stiffness. , 2008, , 11-25.		4
330	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1334-1349.	1.5	4
331	Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. <i>Journal of Cardiac Failure</i> , 2020, 26, 876-884.	0.7	4
332	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 415-427.	1.9	4
333	Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H798-H805.	1.5	4
334	Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 86-92.	0.3	3
335	The Heart Failure Society of America in 2020: A Vision for the Future. <i>Journal of Cardiac Failure</i> , 2012, 18, 90-93.	0.7	3
336	Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. <i>ESC Heart Failure</i> , 2020, 7, 3040-3048.	1.4	3
337	INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 849-860.	1.4	3
338	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	1.2	3
339	Structural components of cardiomyocyte remodeling: Summation. <i>Journal of Cardiac Failure</i> , 2002, 8, S311-S313.	0.7	2
340	Alterations in Ventricular Function. , 2011, , 213-231.		2
341	Response to Letter Regarding Article "Contractile Behavior of the Left Ventricle in Diastolic Heart Failure: With Emphasis on Regional Systolic Function". <i>Circulation</i> , 2006, 114, .	1.6	1
342	Lack of Association Between Spironolactone Use and 30-Day All-Cause Readmission In Hospitalized Medicare Beneficiaries With Systolic Heart Failure Eligible for Spironolactone Therapy. <i>Journal of Cardiac Failure</i> , 2014, 20, S58.	0.7	1

#	ARTICLE	IF	CITATIONS
343	Response to Letters Regarding Article, "Systolic and Diastolic Mechanics in Stress Cardiomyopathy". Circulation, 2015, 131, e372.	1.6	1
344	The Vexing Problem of HFpEF Therapeutics. JACC: Heart Failure, 2021, 9, 371-373.	1.9	1
345	Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF. PLoS ONE, 2022, 17, e0262479.	1.1	1
346	Response to Letters Regarding Article, "Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction". Circulation, 2012, 126, .	1.6	0
347	Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536.	1.2	0
348	Repetitive Acute Hemodynamic Load. JACC Basic To Translational Science, 2019, 4, 542-545.	1.9	0
349	Reply. Journal of the American College of Cardiology, 2020, 76, 2417-2418.	1.2	0
350	Reply. Journal of the American College of Cardiology, 2020, 75, 1501-1502.	1.2	0
351	Pathophysiology of Heart Failure With a Preserved Ejection Fraction: Measurements and Mechanisms Causing Abnormal Diastolic Function. , 2021, , 11-30.		0
352	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030.	0.7	0
353	Assessment of Left Ventricular Diastolic Function in Mice. Developments in Cardiovascular Medicine, 2001, , 223-236.	0.1	0
354	A Finite Element Model for Drop-on-Demand Printing of Designer Hybrid Cardiovascular Constructs. , 2005, , .		0
355	Abstract 15308: SPARC Deletion Suppresses Age-related Cardiac Inflammation. Circulation, 2014, 130, .	1.6	0
356	Abstract 17955: Reduction in 30-day Rehospitalization After Discharge From a Heart Failure Admission in Patients Receiving LCZ696 versus Enalapril: PARADIGM-HF. Circulation, 2015, 132, .	1.6	0
357	Quantification of Diastolic Viscoelastic Properties of Isolated Cardiac Muscle Cells. , 2001, , .		0
358	And The Band Played On: Persistent Fibrosis After Unbanding Reveals Sex-Dependent Differences in Rats. American Journal of Physiology - Heart and Circulatory Physiology, 0, , .	1.5	0